CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CytoSorbents (NASDAQ: CTSO), a leader in blood purification for treating life-threatening conditions in intensive care and cardiac surgery, has announced it will report its second quarter 2024 operating and financial results on Tuesday, August 13, 2024, after market close. The company's management will host a live conference call, presentation webcast, and Q&A session at 4:30 PM EDT on the same day.
Investors and interested parties can access the live webcast through the provided link or join via phone using the toll-free dial-in number. Participants are advised to dial in about 10 minutes before the call starts. An archived recording of the conference call will be available on the company's website under the Investor Relations section.
CytoSorbents (NASDAQ: CTSO), leader nella purificazione del sangue per il trattamento di condizioni potenzialmente letali in terapia intensiva e nella chirurgia cardiaca, ha annunciato che renderà noti i suoi risultati operativi e finanziari del secondo trimestre 2024 martedì 13 agosto 2024, dopo la chiusura del mercato. La direzione dell'azienda ospiterà una conferenza telefonica dal vivo, una presentazione in streaming e una sessione di domande e risposte alle 4:30 PM EDT dello stesso giorno.
Gli investitori e le parti interessate possono accedere alla webconferenza dal vivo tramite il link fornito o partecipare telefonicamente utilizzando il numero verde. Si consiglia ai partecipanti di collegarsi circa 10 minuti prima dell'inizio della chiamata. Una registrazione archiviata della conferenza sarà disponibile sul sito web dell'azienda nella sezione Relazioni con gli Investitori.
CytoSorbents (NASDAQ: CTSO), líder en purificación de sangre para el tratamiento de condiciones que amenazan la vida en cuidados intensivos y cirugía cardiaca, ha anunciado que reportará sus resultados operativos y financieros del segundo trimestre de 2024 el martes 13 de agosto de 2024, después del cierre del mercado. La dirección de la empresa organizará una conferencia telefónica en vivo, una presentación por webcast y una sesión de preguntas y respuestas a las 4:30 PM EDT del mismo día.
Los inversores y partes interesadas pueden acceder a la webcast en vivo a través del enlace proporcionado o unirse por teléfono usando el número de marcado gratuito. Se aconseja a los participantes que se conecten unos 10 minutos antes de que comience la llamada. Una grabación archivada de la conferencia estará disponible en el sitio web de la empresa en la sección de Relaciones con Inversores.
CytoSorbents (NASDAQ: CTSO)는 중환자 치료 및 심장 수술에서 생명을 위협하는 상태를 치료하기 위한 혈액 정화 분야의 선두주자로, 2024년 2분기 운영 및 재무 결과를 2024년 8월 13일 화요일에 시장 마감 후 발표할 것이라고 발표했습니다. 회사 경영진은 같은 날 오후 4:30 EDT에 라이브 컨퍼런스 콜, 프레젠테이션 웹캐스트 및 질의응답 세션을 주최할 예정입니다.
투자자 및 이해관계자는 제공된 링크를 통해 라이브 웹캐스트에 접근하거나 무료 전화 다이얼 번호를 사용하여 전화로 참여할 수 있습니다. 참가자는 통화 시작 약 10분 전에 연결하는 것이 좋습니다. 회의 통화의 보관 녹음은 회사 웹사이트의 투자자 관계 섹션에서 제공될 것입니다.
CytoSorbents (NASDAQ: CTSO), un leader dans la purification du sang pour traiter des conditions mettant la vie en danger en soins intensifs et en chirurgie cardiaque, a annoncé qu'il publiera ses résultats financiers et opérationnels du deuxième trimestre 2024 le mardi 13 août 2024, après la fermeture du marché. La direction de l'entreprise animera une conférence téléphonique en direct, un webinaire de présentation et une séance de questions-réponses à 16h30 EDT le même jour.
Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct via le lien fourni ou rejoindre par téléphone en utilisant le numéro gratuit. Il est conseillé aux participants de se connecter environ 10 minutes avant le début de l'appel. Un enregistrement archivé de la conférence sera disponible sur le site web de l'entreprise dans la section Relations avec les Investisseurs.
CytoSorbents (NASDAQ: CTSO), ein führendes Unternehmen in der Blutreinigung zur Behandlung lebensbedrohlicher Zustände in der Intensivpflege und Herzchirurgie, hat bekannt gegeben, dass es seine Operativen und finanziellen Ergebnisse für das zweite Quartal 2024 am Dienstag, den 13. August 2024, nach Börsenschluss veröffentlicht. Das Management des Unternehmens wird am selben Tag um 16:30 Uhr EDT eine Live-Konferenzschaltung, eine Präsentation per Webcast und eine Frage-Antwort-Runde veranstalten.
Investoren und Interessierte können über den bereitgestellten Link auf den Live-Webcast zugreifen oder über die gebührenfreie Telefonnummer teilnehmen. Teilnehmern wird empfohlen, etwa 10 Minuten vor Beginn der Konferenz einzuwählen. Eine archivierte Aufzeichnung der Konferenz wird auf der Website des Unternehmens im Bereich Investor Relations zur Verfügung stehen.
- Company is maintaining regular investor communication by hosting a quarterly earnings call
- CytoSorbents continues to be listed on NASDAQ, indicating compliance with listing requirements
- None.
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024.
CytoSorbents’ management will host a live conference call, presentation webcast, and a question and answer session starting at 4:30PM EDT the same day.
Webcast Details:
Date: Tuesday, August 13, 2024
Time: 4:30 PM EDT
Live webcast link: https://edge.media-server.com/mmc/p/smuwcy9a
Conference ID: 7567925
Participant Dial-In:
Participant Dial-in toll-free: (888) 596-4144
Passcode: 7567925
It is recommended that participants dial in approximately 10 minutes prior to the start of the call.
An archived recording of the conference call will be available under the Investor Relations section of the Company’s website at https://ir.cytosorbents.com/
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. As of March 31, 2024, more than 237,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.
The DrugSorb™-ATR antithrombotic removal system, an investigational device based on the same polymer technology as CytoSorb, has received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The Company has completed the FDA-approved, randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 140 patients at approximately 30 centers in U.S. and Canada to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. This pivotal study is intended to support U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in this application.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, statements about potential exposures resulting from our cash positions, representations and contentions, and the timing of our expected regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and X
U.S. Company Contact:
Kathleen Bloch, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
+1 (732) 398-5429
kbloch@cytosorbents.com
Investor Relations Contact:
Eric Ribner
LifeSci Advisors, LLC
250 W 55th St, #3401
New York, NY 10019
+1 (646) 751-4363
ir@cytosorbents.com
FAQ
When will CytoSorbents (CTSO) report its Q2 2024 financial results?
What time is CytoSorbents' (CTSO) Q2 2024 earnings call scheduled for?
How can investors access CytoSorbents' (CTSO) Q2 2024 earnings call?
Where can I find the archived recording of CytoSorbents' (CTSO) Q2 2024 earnings call?
